UK-based Small Pharma Inc will commence trading on the TSX Venture Exchange (via RTO) on May 6, 2021, under the symbol "DMT".
Exploring the companies and themes that make up this emerging and exciting new sector
Red Light Holland Receives Patent Pending Status For 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland granted patent pending status for its 'Find Your Dose' microdosing kit.
Psyched Wellness Signs Supply Agreement for Amanita Muscaria
Psyched Wellness has contracted with a Lithuanian company to obtain 200 kgs of Amanita muscaria mushroom caps.
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Mydecine reports that it's Phase IIa clinical trial is underway at three sites. Net loss for the year of CAD$26.9 million. Current cash ~CAD$30 million.
The NEXT Psychedelic Stock To Uplist On The NASDAQ?
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Numinus reports its Q2 2021 results. Cash balance of CAD$28.5 million. Net loss of CAD$4.2 million.
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.
Small Pharma Completes Reverse Take-Over Transaction
UK-based Small Pharma Inc prepares to go public on the TSXV via RTO, having raised CAD$58 million for its qualifying transaction
Wesana Health and Debut Announce Receipt of Conditional Approval for CSE Listing
Wesana Health obtains conditional approval from the CSE to commence trading, via RTO with Debut Diamonds (CSE:DDI).
COMPASS Pathways launches proposed public offering
Compass Pathways plans to issue 4,000,000 new shares via prospectus, with an option to sell an additional 600,000 shares.
Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1
Psyched Wellness continues pre-clinical work on its AME-1 extract.
Second-Chance Buying Opportunity With Psychedelic Stock Warrants
In 2020, investors were able to reap spectacular returns from psychedelic stock warrants. With a new rally starting in the sector, a there is a NEW opportunity in these warrants.